Quetiapine
What is this? Quetiapine is a medicine used to treat mental health problems like schizophrenia and bipolar disorder.
What's happening? There is a shortage of quetiapine tablets in some EU countries.
Does this affect me? If you take quetiapine, you may be affected.
What should I do? Talk to your pharmacist or doctor before making any changes.
🤖 Tämä selkeäsanainen yhteenveto on tuotettu viranomaisen ilmoituksesta tekoälyä käyttäen. Se on tarkoitettu yleisluontoiseen tiedottamiseen — ei lääkärinlausunto. Terveydestäsi päättäessäsi ota aina yhteyttä apteekkiin tai lääkäriin ja lue alla oleva virallinen lähde.
📋 Virallisen viraston tiedotteesta
Päivitetty 1 viikko sitten- Viimeksi päivitetty
- 04/05/2026
- Ensimmäisen kerran julkaistu
- 11/03/2025
- Lääkkeet, joihin vaikutus kohdistuu
- Quetiapine
- Vaikutukset vahvuuksiin
- 50 mg150 mg200 mg300 mg400 mg
- Oletettu ratkaisu
- Within the second quarter of 2027
- Toimituksen lyhytaikainen tilanne
- Ongoing
- Terapeuttinen alue (MESH)
- SchizophreniaBipolar DisorderDepressive Disorder
- Toimituksen alun puute
- 11/03/2025
- Vaihtoehtojen saatavuus
- Yes
- Lääkemuodot, joihin vaikuttaa
- Extended-release tablet
Sivun sisältö
Puutetiedot
There is a shortage of extended-release tablets of quetiapine in some EU/EEA (European Union/European Economic Area) Member States.
Quetiapine-containing medicines are used to treat psychiatric disorders including:
- schizophrenia, a mental illness with symptoms such as disorganised thinking and speech, hallucinations (hearing or seeing things that are not there), suspiciousness and delusions (false beliefs);
- bipolar disorder, a mental illness in which patients have manic episodes (periods of abnormally high mood), alternating with periods of normal mood, as well as episodes of depression;
- certain types of depression.
Quetiapine-containing medicines are available as tablets that are taken by mouth, in either an immediate-release or extended-release formulation. Extended release means that the active substance in the medicine is released slowly over time.
Several Member States are experiencing an increase in demand for medicines containing extended-release quetiapine. In addition, the manufacturer that supplies this formulation to several companies in the EU has faced a production issue. These events combined have led to a shortage of this medicine in the EU/EEA.
The shortage is expected to continue through the second quarter of 2027.
The shortage affects the following countries where the product is marketed:Austria, Belgium, Bulgaria, Croatia, Czechia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Luxembourg, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain and Sweden.
This information may change. For up-to-date information about the status of a medicine shortage in a particular Member State, consult the national shortage register or contact the national competent authority.
EMA’s Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) and EMA’s shortages working party (Medicines Shortages Single Point of Contact – SPOC - working party) are closely monitoring the supply situation and are engaging with impacted marketing authorisation holders, as well as alternative marketing authorisation holders to mitigate the impact of the supply shortage. This includes assistance from EMA’s solidarity mechanism whereby affected Member States can request help from other Member States in obtaining medicine stocks.
- Extended-release tablets of quetiapine are in short supply; this is expected to continue through the second quarter of 2027.
- Before initiating treatment with extended-release tablets of quetiapine, you should check with your national competent authority in case they have issued national recommendations.
- If the brand that you prescribe or dispense is not available, other extended-release quetiapine products may be available. If not, you should consider switching patients to an alternative treatment. Immediate-release quetiapine products may also be available, depending on the country.
- For additional information consult your country’s shortage register or contact your national competent authority. Your national competent authority may have issued further national recommendations.
- Extended-release tablets of quetiapine are in short supply; this is expected to continue through the second quarter of 2027.
- If the brand you use is unavailable, there may be alternative extended-release quetiapine products authorised in your country, immediate-release quetiapine products or other treatment alternatives. Your doctor will discuss suitable options with you.
- Contact your pharmacy or doctor well before your current supply runs out.
- If you have any questions, speak to your doctor or pharmacist.
- For additional information, consult your country’s shortage register or contact your national competent authority.
Lyhytaikainen puute
Several Member States are experiencing an increase in demand for medicines containing extended-release quetiapine. In addition, the manufacturer that supplies this formulation to several companies in the EU has faced a production issue. These events combined have led to a shortage of this medicine in the EU/EEA.
The shortage is expected to continue through the second quarter of 2027.
Vaikutusalueella olevat jäsenvaltiot
The shortage affects the following countries where the product is marketed:Austria, Belgium, Bulgaria, Croatia, Czechia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Luxembourg, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain and Sweden.
This information may change. For up-to-date information about the status of a medicine shortage in a particular Member State, consult the national shortage register or contact the national competent authority.
Valvonta puutteesta
EMA’s Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) and EMA’s shortages working party (Medicines Shortages Single Point of Contact – SPOC - working party) are closely monitoring the supply situation and are engaging with impacted marketing authorisation holders, as well as alternative marketing authorisation holders to mitigate the impact of the supply shortage. This includes assistance from EMA’s solidarity mechanism whereby affected Member States can request help from other Member States in obtaining medicine stocks.
Suositus terveydenhuollon ammattilaisille
- Extended-release tablets of quetiapine are in short supply; this is expected to continue through the second quarter of 2027.
- Before initiating treatment with extended-release tablets of quetiapine, you should check with your national competent authority in case they have issued national recommendations.
- If the brand that you prescribe or dispense is not available, other extended-release quetiapine products may be available. If not, you should consider switching patients to an alternative treatment. Immediate-release quetiapine products may also be available, depending on the country.
- For additional information consult your country’s shortage register or contact your national competent authority. Your national competent authority may have issued further national recommendations.
Suositukset potilaille ja hoitajille
- Extended-release tablets of quetiapine are in short supply; this is expected to continue through the second quarter of 2027.
- If the brand you use is unavailable, there may be alternative extended-release quetiapine products authorised in your country, immediate-release quetiapine products or other treatment alternatives. Your doctor will discuss suitable options with you.
- Contact your pharmacy or doctor well before your current supply runs out.
- If you have any questions, speak to your doctor or pharmacist.
- For additional information, consult your country’s shortage register or contact your national competent authority.
Avainasiat
- Medicines affected
- Quetiapine
- Supply shortage status
- Ongoing
- Therapeutic area (MESH)
- Schizophrenia
- Bipolar Disorder
- Depressive Disorder
- Pharmaceutical forms affected
- Extended-release tablet
- Strengths affected
- 50 mg
- 150 mg
- 200 mg
- 300 mg
- 400 mg
- Availability of alternatives
- Yes
Avainpäivät
- Start of supply shortage
- Expected resolution
- Within the second quarter of 2027
- First published
- Last updated
Lääketieteelliset tiedot
🔬 Lääketieteelliset / tekniset tiedot ammattilaisille
Forms: Extended-release tablet · Strengths: 50 mg;150 mg;200 mg;300 mg;400 mg · Area: Schizophrenia;Bipolar Disorder;Depressive Disorder · Alternatives: Yes
Kaikki tämän sivun tiedot perustuvat virallisen viraston tiedotteeseen. Käännämme ja tiivistämme ne; emme lisää tai muokkaa faktoja.